A Randomized, Double-blind, Placebo-controlled Clinical Study to Investigate the efficacy of Herring Roe Oil for treatment of Psoriasis

Kåre Steinar Tveit, Karl Albert Brokstad, Rolf K Berge, Per Christian Sæbø, Hogne Hallaråker, Stian Brekke, Nils Meland, Bodil Bjørndal, Kåre Steinar Tveit, Karl Albert Brokstad, Rolf K Berge, Per Christian Sæbø, Hogne Hallaråker, Stian Brekke, Nils Meland, Bodil Bjørndal

Abstract

The effect of omega-3 polyunsaturated fatty acid supplements in patients with psoriasis vulgaris has previously been investigated, but interventions varied in source, composition, dose, administration route and duration of treatment. The observed beneficial effects in patients with psoriasis vulgaris using herring roe oil as a dietary supplement prompted this investigation. This randomised, double-blind and placebo-controlled study was designed and performed to explore the efficacy and safety of herring roe oil supplementation in 64 patients with plaque psoriasis (ClinicalTrials.gov: NCT03359577). The primary end-point was comparing the change in mean Psoriasis Area Severity Index (PASI) scores in the herring roe oil treatment group and the placebo group from baseline to week 26. In the intention-to-treat population, a statistically significant improvement in the mean PASI score was observed with herring roe oil compared to placebo at 26 weeks. In the recruited patient group, the measured improvement was greatest in patients with a PASI score from 5.5-9.9 at baseline.

Keywords: omega-3; phospholipids; psoriasis; herring roe oil.

Figures

Fig. 1
Fig. 1
Flow diagram. HRO: herring roe oil.
Fig. 2
Fig. 2
Psoriasis on the back of a patient in the active treatment group at week 26 (Psoriasis Area Severity Index: 0.7).
Fig. 3
Fig. 3
Changes in Psoriasis Area Severity Index (PASI) score from baseline to week 26, in herring roe oil (HRO) and placebo treated patients with baseline PASI >5.5 (n = 31). Boxplot showing minimum, maximum, Q1 (25th percentile), Q3 (75th percentile), median (line) and mean (diamond) changes in both treatment groups. Patients in the sub-population were evenly distributed in the treatment groups, HRO n = 15; placebo n = 16.

References

    1. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol 2013; 149: 1180–1185.
    1. Mayser P, Grimm H, Grimminger F. n-3 Fatty acids in psoriasis. Br J Nutr 2002; 87: 77–82.
    1. Balbás GM, Regaña MS, Millet PU. Study on the use of omega-3 fatty acids as a therapeutic supplement in treatment of psoriasis. Clin Cosmet Investig Dermatol 2011; 4: 73–77.
    1. Guida B, Napoleone A, Trio R, Nastasi A, Balato N, Laccetti R, et al. . Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. Clin Nutr Edinb Scotl 2014; 33: 399–405.
    1. Upala S, Yong WC, Theparee T, Sanguankeo A. Effect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic review. Int J Rheum Dis 2017; 20: 442–450.
    1. Khorsan R, Crawford C, Ives JA, Walter AR, Jonas WB. The effect of omega-3 fatty acids on biomarkers of inflammation: a rapid evidence assessment of the literature. Mil Med 2014; 179: 2–60.
    1. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta 2010; 1801: 1260–1273.
    1. Cook CM, Hallaråker H, Sæbø PC, Innis SM, Kelley KM, Sanoshy KD, et al. . Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols. Prostaglandins Leukot Essent Fatty Acids 2016; 111: 17–24.
    1. Ramprasath VR, Eyal I, Zchut S, Jones PJH. Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis 2013; 12: 178.
    1. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244.
    1. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64: 65–73.
    1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
    1. Dupont P. Traitement du psoriasis par la lécithine marine. Phytothérapie 2006; 4: 15–22.
    1. Sgarbi C, Villa R, Bedin V, Franco M. Oral supplementation of omega-3 as an adjunct in the treatment of psoriasis. Available from: , 2012.
    1. McCusker MM, Grant-Kels JM. Healing fats of the skin: the structural and immunologic roles of the omega-6 and omega-3 fatty acids. Clin Dermatol 2010; 28: 440–451.
    1. Allen MJ, Fan Y-Y, Monk JM, Hou TY, Barhoumi R, McMurray DN, et al. . n-3 PUFAs reduce T-helper 17 cell differentiation by decreasing responsiveness to interleukin-6 in isolated mouse splenic CD4+ T cells. J Nutr 2014; 144: 1306–1313.
    1. Bjørndal B, Strand E, Gjerde J, Bohov P, Svardal A, Diehl BW, et al. . Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults. Lipids Health Dis 2014; 13: 82.
    1. Caputo MP, Radlowski EC, Lawson MA, Antonson AM, Watson JE, Matt SM, et al. . Herring roe oil supplementation alters microglial cell gene expression and reduces peripheral inflammation after immune activation in a neonatal piglet model. Brain Behav Immun 2019; 81: 455–469.
    1. Raederstorff D, Pantze M, Bachmann H, Moser U. Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation. Int Arch Allergy Immunol 1996; 111: 284–290.
    1. Saito-Sasaki N, Sawada Y, Mashima E, Yamaguchi T, Ohmori S, Yoshioka H, et al. . Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression. Sci Rep 2018; 8: 5522.
    1. Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, et al. . Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol Ther 2019; 9: 5–18.
    1. Andres P, Poncet M, Farzaneh S, Soto P. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol 2006; 5: 328–332.
    1. Vázquez-López F, Marghoob AA. Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis. J Am Acad Dermatol 2004; 51: 811–813.
    1. Stein Gold LF. Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence. Semin Cutan Med Surg 2016; 35: 36–45.
    1. NICE . Psoriasis: assessment and management. Clinical guideline. [Internet]. National Institute for Health and Care Excellence; 2012. [cited 2019 Dec 19]. Available from: .

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit